Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

BROKER RATINGS: Exane BNP downgrades three property companies

Thu, 06th May 2021 09:46

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

EXANE BNP CUTS BRITISH LAND CO TO 'NEUTRAL' ('OUTPERFORM') - TARGET 500 PENCE

----------

CREDIT SUISSE RAISES BARRATT DEVELOPMENTS TARGET TO 838 (780) PENCE - 'OUTPERFORM'

----------

LIBERUM RAISES ASTRAZENECA PRICE TARGET TO 9,220 (9,060) PENCE - 'BUY'

----------

JPMORGAN RAISES MELROSE INDUSTRIES TARGET TO 215 (210) PENCE - 'OVERWEIGHT'

----------

DEUTSCHE BANK RAISES COMPASS GROUP PRICE TARGET TO 1,720 (1,630) PENCE - 'BUY'

----------

GOLDMAN SACHS CUTS BUNZL PRICE TARGET TO 2,610 (2,630) PENCE - 'NEUTRAL'

----------

BERENBERG RAISES FLUTTER PRICE TARGET TO 14,700 (14,300) PENCE - 'HOLD'

----------

BERENBERG RAISES NATIONAL GRID TO 'BUY' ('HOLD') - PRICE TARGET 1,100 (930) PENCE

----------

RBC RAISES FRESNILLO PRICE TARGET TO 800 (775) PENCE - 'UNDERPERFORM'

----------

BARCLAYS RAISES BT GROUP PRICE TARGET TO 190 (170) PENCE - 'OVERWEIGHT'

----------

JEFFERIES RAISES RECKITT BENCKISER PRICE TARGET TO 6,050 (5,950) PENCE - 'HOLD'

----------

GOLDMAN RAISES HIKMA PHARMACEUTICAL PRICE TARGET TO 2,830 (2,780) PENCE - 'BUY'

----------

FTSE 250

----------

EXANE BNP CUTS GREAT PORTLAND TO 'UNDERPERFORM' ('NEUTRAL') - TARGET 630 (670) PENCE

----------

EXANE CUTS DERWENT LONDON TO 'NEUTRAL' ('OUTPERFORM') - TARGET 3,390 (3,540) PENCE

----------

CITIGROUP RESUMES SHAFTESBURY WITH 'NEUTRAL'

----------

LIBERUM RAISES TRITAX BIG BOX PRICE TARGET TO 210 (200) PENCE - 'BUY'

----------

RBC RAISES RATHBONE BROTHERS PRICE TARGET TO 2,020 (1,975) PENCE - 'OUTPERFORM'

----------

DEUTSCHE BANK CUTS DIRECT LINE PRICE TARGET TO 340 (350) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES VIRGIN MONEY PRICE TARGET TO 240 (230) PENCE - 'BUY'

----------

BARCLAYS RAISES UDG HEALTHCARE PRICE TARGET TO 975 (920) PENCE - 'OVERWEIGHT'

----------

CREDIT SUISSE RAISES ITV PRICE TARGET TO 147 PENCE - 'OUTPERFORM'

----------

BARCLAYS RAISES ITV PRICE TARGET TO 130 (125) PENCE - 'EQUAL WEIGHT'

----------

BERENBERG RAISES ITV PRICE TARGET TO 117 (112) PENCE - 'HOLD'

----------

BERENBERG RAISES IP GROUP PRICE TARGET TO 151 (148) PENCE - 'BUY'

----------

RBC RAISES CENTAMIN PRICE TARGET TO 120 (115) PENCE - 'SECTOR PERFORM'

----------

OTHER MAIN MARKET AND AIM

----------

LIBERUM RAISES CVS GROUP PRICE TARGET TO 2,200 (1,800) PENCE - 'HOLD'

----------

RBC CUTS BOOHOO PRICE TARGET TO 380 (420) PENCE - 'SECTOR PERFORM'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...

Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.